4 minute read
Oct. 29, 2022

GB1211: an Oral Galectin-3 Inhibitor for Fibrotic Disease


oral galectin-3 inhibitor Ph. I/II candidate in cancer and liver diseases LLE and PK opt. from a prev. clinical candidate J. Med. Chem., Sep 26, 2022 Galecto Biotech, Gothenburg, SE

Drug Hunter Team

GB1211 (Galecto Biotech) is an oral galectin-3 inhibitor under development for fibrotic disease. First described in 1971, galectin-3 , a unique subtype of a 15-member family of carbohydrate-binding proteins, has been implicated in a host of different diseases, such as cancer, liver cirrhosis, and atherosclerosis. Incredibly, over [...]



Other molecules you may be interested in